PPA1 and ovarian carcinoma: The use of GSK-3β inhibitors blocks the process by which PPA1 promotes β-catenin nuclear translocation, implying that PPA1 promotes EMT in ovarian cancer by participating in β-catenin dephosphorylation (Figure 2; Table 1).